Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3207-3216

  Koffeman, Eva C ^a,b   Genovese, Mark ^c   Amox, Diane ^a   Keogh, Elissa ^d   Santana, Ernesto ^e   Matteson, Eric L ^f   Kavanaugh, Arthur ^a   Molitor, Jerry A ^g   Schiff, Michael H ^h   Posever, James O ^d   Bathon, Joan M ⁱ   Kivitz, Alan J ^j   Samodal, Rodrigo ^k   Belardi, Francis ^k   Dennehey, Carolyn ^l   Van Den Broek, Theo ^d   Van Wijk, Femke ^b   Zhang, Xiao ^m   Zieseniss, Peter ^a   Le, Tho ^a,b   Prakken, Berent A ^b   Cutter, Gary C ^m   Albani, Salvatore ^a,b,d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EUREKA Institute for Translational Medicine   (Italy)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Instituto Mexicano del Seguro Hospital NO 20   (Mexico)

^f MAYO CLINIC   (United States)

^g BENAROYA RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j Altoona Center for Clinical Resarch   (United States)

^k GUTHRIE RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; INTERLEUKIN 10; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE DERIVATIVE; PEPTIDE DNAJP1; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ADULT; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HSP40 HEAT-SHOCK PROTEINS; HUMANS; HYDROXYCHLOROQUINE; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; INTERLEUKIN-10; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350521825     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24916     Document Type: Article

References (43)

1. Pisetsky DS. Rheumatology in the current era: the challenge of success. Nat Clin Pract Rheumatol 2008;4:165.
2. Firestein GS. Inhibiting inflammation in rheumatoid arthritis. N Engl J Med 2006;354:80-82
3. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003;48:906-916 (Pubitemid 36418232)
4. Olsen NJ, Stein CM. Drug therapy: new drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179
5. Kahn KL, MacLean CH, Liu H, Rubenstein LZ, Wong AL, Harker JO, et al. Application of explicit process of care measurement to rheumatoid arthritis: moving from evidence to practice. Arthritis Rheum 2006;55:884-891 (Pubitemid 44917461)
6. Singh R, Robinson DB, El Gabalawy HS. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr Opin Rheumatol 2005;17:274-279 (Pubitemid 40616572)
7. Pollard L, Choy E. Rheumatoid arthritis: non-tumor necrosis factor targets. Curr Opin Rheumatol 2005;17:242-246 (Pubitemid 40616569)
8. Cope AP, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004;16:780-786 (Pubitemid 39423669)
9. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-167 (Pubitemid 44691882)
10. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, Group FS. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24 Suppl 43:S077-82.
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-415 (Pubitemid 351650575)
12. Pisetsky DS. A landmark study on treatment strategies for rheumatoid arthritis. Arthritis Rheum 2008;58 Suppl 2:S123-5.
13. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-784
14. Steinman L. Immune therapy for autoimmune diseases. Science 2004;305:212-216
15. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, et al. New reagents on the horizon for immune tolerance. Annu Rev Med 2007;58:329-346 (Pubitemid 46706518)
16. Kronenberg M, Rudensky A. Regulation of immunity by selfreactive T cells. Nature 2005;435:598-604.
17. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006;212:203-216 (Pubitemid 44116710)
18. Albert LJ, Inman RD. Mechanisms of disease: molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-2074
19. Prakken B, Albani S. Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis. Arthritis Rheum 2007;56:389-392 (Pubitemid 46271963)
20. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007;204:33-39 (Pubitemid 46148753)
21. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheuma- toid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;200:277-285 (Pubitemid 39031247)
22. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108:253-261
23. La Cava A, Nelson JL, Ollier WE, MacGregor A, Keystone EC, Thorne JC, et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest 1997;100:658-663 (Pubitemid 27340514)
24. Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996;17:466-470 (Pubitemid 26323315)
25. Albani S, Keystone EC, Nelson JL, Ollier WE, La Cava A, Montemayor AC, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995;1: 448-452
26. Albani S, Tuckwell JE, Carson DE, Roudier J. The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leucocyte antigen DRB10401 molecule. J Clin Invest 1992;89:327-331
27. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003;362:469-476 (Pubitemid 36999714)
28. Van Eden W, van Der ZR, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005;5:318-330 (Pubitemid 40516157)
29. Panayi GS. Even though T-cell-directed trials have been of limited success, is there reason for optimism? Nat Clin Pract Rheumatol 2006;2:58-59
30. Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. J Clin Invest 2004;114: 1227-1232 (Pubitemid 40385291)
31. Kamphuis S, Massa M, Albani S, Prakken B. Tolerogenic immune responses to novel T cell epitopes from heat shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366:50-56 (Pubitemid 40956530)
32. Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001; 104:367-376
33. Massa M, Passalia M, Manzoni SM, Campanelli R, Ciardelli L, Puga Yung G, et al. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1648-1657 (Pubitemid 46764094)
34. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-1194
35. Prakken BJ, Samodal R, Giannoni F, Puga Yung G, Scavulli J, Amox D, et al. Epitope-specific immunotherapy induces immune deviation of pro-inflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004;101:4228-4233 (Pubitemid 38405911)
36. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-1353 (Pubitemid 14231480)
37. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
38. Schiff M, Weaver A. Keystone E, Moreland L, Spencer-Green G. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials [abstract]. Arthritis Rheum 1999;42 Suppl:S81.
39. Morel JG, Bokossa MC, Neerchal NK. Small sample correction for the variance of GEE estimators. Biometric J 2003;45:395-409.
40. Guo X, Pan W, Connett JE, Hannan PJ, French SA. Small-sample performance of the robust score test and its modifications in generalized estimating equations. Stat Med 2005;24:3479-3495 (Pubitemid 41645387)
41. Albani S, Prakken B. T cell epitope-specific therapy for rheumatic diseases. Arthritis Rheum 2006;54:19-25. (Pubitemid 43122182)
42. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8:1246-1254 (Pubitemid 350011764)
43. Roord ST, Zonneveld-Huijssoon E, Le T, Yung GP, Koffeman E, Ronaghy A, et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 2006;1:e87.